



Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: Mr. Ian Burkhart

Committee: Patient Engagement Advisory Committee

Meeting Date: September 6, 2023

I acknowledge that contingent upon public disclosure of the following financial interest(s) related to the agenda item on September 6, 2023, is to discuss and make recommendations on the topic of “Advancing Health Equity in Medical Devices”, I may be considered for participation in the advisory committee meeting described above.

Type of Interest	Nature	Magnitude
I. Personal/Immediate Family		
Personal. SGE serves as a consultant and is compensated by charitable organization.	SGE serves as a consultant on a contract from a medical device firm.	Amount to SGE is between \$5,001 and \$15,000.
II. Other Imputed Interests		
Imputed SGE serves as President with fiduciary and fundraising responsibilities for a charitable organization.	The charitable organization receives contributions for consultant/research contract from a medical device firm.	Amount to the charitable organization is between \$50,001 and \$70,000.

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

/s/ Signature

August 18, 2023
Date